$-0.14 EPS Expected for Check-Cap Ltd. (CHEK)

February 12, 2018 - By Hazel Jackson

 $ 0.14 EPS Expected for Check Cap Ltd. (CHEK)

Analysts expect Check-Cap Ltd. (NASDAQ:CHEK) to report $-0.14 EPS on March, 8.They anticipate $0.01 EPS change or 6.67 % from last quarter’s $-0.15 EPS. After having $-0.13 EPS previously, Check-Cap Ltd.’s analysts see 7.69 % EPS growth. The stock increased 7.58% or $0.05 during the last trading session, reaching $0.71. About 64,917 shares traded. Check-Cap Ltd. (NASDAQ:CHEK) has declined 2.26% since February 12, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.

Check-Cap Ltd. (NASDAQ:CHEK) Ratings Coverage

Among 4 analysts covering Check-Cap (NASDAQ:CHEK), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Check-Cap had 11 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, November 28 by H.C. Wainwright. Maxim Group initiated it with “Buy” rating and $18 target in Thursday, October 8 report. The rating was maintained by Maxim Group with “Buy” on Tuesday, May 30. The stock of Check-Cap Ltd. (NASDAQ:CHEK) earned “Buy” rating by H.C. Wainwright on Friday, August 11. The stock of Check-Cap Ltd. (NASDAQ:CHEK) has “Buy” rating given on Thursday, January 19 by Rodman & Renshaw. H.C. Wainwright maintained Check-Cap Ltd. (NASDAQ:CHEK) on Thursday, January 11 with “Buy” rating. The stock has “Buy” rating by Chardan Capital Markets on Wednesday, March 16. The stock of Check-Cap Ltd. (NASDAQ:CHEK) has “Buy” rating given on Wednesday, July 22 by Chardan Capital Markets. The firm earned “Buy” rating on Tuesday, January 19 by Maxim Group. Chardan Capital Markets maintained it with “Buy” rating and $4 target in Friday, May 20 report.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. The company has market cap of $13.68 million. The Company’s C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. It currently has negative earnings.

More notable recent Check-Cap Ltd. (NASDAQ:CHEK) news were published by: Prnewswire.com which released: “Check-Cap Ltd. Announces $2.5 Million Registered Direct Offering” on November 20, 2017, also Prnewswire.com with their article: “Check-Cap Receives CE Mark Approval for C-ScanĀ®” published on January 10, 2018, Prnewswire.com published: “Check-Cap Announces Advancement in GE Healthcare Manufacturing Collaboration” on December 05, 2017. More interesting news about Check-Cap Ltd. (NASDAQ:CHEK) were released by: Prnewswire.com and their article: “Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification” published on January 19, 2018 as well as Prnewswire.com‘s news article titled: “Check-Cap Ltd. Announces Closing of $2.5 Million Registered Direct Offering” with publication date: November 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.